Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis

American Journal of Hematology

Volumn 91, Issue 3, 2016, Pages E12-E14

  Patnaik, Mrinal M ^a   Lasho, Terra L ^a   Finke, Christy M ^a   Pardanani, Animesh ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PDGFRB PROTEIN, HUMAN;

BONE MARROW BIOPSY; CHROMOSOME TRANSLOCATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; EOSINOPHILIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; LETTER; MONOCYTE MACROPHAGE PRECURSOR CELL; MONOCYTOSIS; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SPLICEOSOME; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; AGED; BLOOD; DISEASE FREE SURVIVAL; ELECTRONIC HEALTH RECORD; FACTUAL DATABASE; GENETICS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTE; MYELOPROLIFERATIVE DISORDERS; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; ELECTRONIC HEALTH RECORDS; GENE REARRANGEMENT; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTES; MYELOPROLIFERATIVE DISORDERS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 84959165302     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24267     Document Type: Letter

References (8)

1. Swederlow S, Camp E, Harris NL, Jaffe ES, Stefano PA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2008.
2. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-487.
3. Pardanani A, Ketterling RP, Li CY, et al. FIP1L1-PDGFRA in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006;30:965-970.
4. Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 2014;123:3574-3577.
5. Gotlib J. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Am J Hematol 2014;89:325-337.
6. Wassie EA, Itzykson R, Lasho TL, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: A Mayo Clinic-French Consortium Study. Am J Hematol 2014;89:1111-1115.
7. Golub TR, Barker GF, Lovett M, et al. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994;77:307-316.
8. Parikh SA, Tefferi A. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013;88:967-974.